Publication

Article

Oncology Nursing News
June 2013
Volume 7
Issue 4

Big Ten Cancer Centers Form Research Group

Author(s):

While competition is the hallmark of the powerhouse sports teams of the Big Ten Conference, collaboration will be the key for a research initiative recently launched by cancer centers at most of the same universities.

While competition is the hallmark of the powerhouse sports teams of the Big Ten Conference, collaboration will be the key for a research initiative recently launched by cancer centers at most of the same universities.

The Big Ten Cancer Research Consortium will cooperate on clinical trials, with a particular emphasis on molecular diagnostics, in an effort that is expected to generate advancements as well as expand opportunities for junior faculty and fellows, officials said in announcing the new group in Chicago.

“This is a rare opportunity for the universities to work together as part of a regional team science initiative to advance cancer research,” said Patrick J. Loehrer, Sr, MD, director of the Indiana University Melvin and Bren Simon Cancer Center, in a statement. “The advantage of this, particularly during a time of austerity for research, is that we can build upon the strengths of the institutions and fortify some of the shortcomings. This allows us to be lean, efficient, but most importantly, collaborative.”

The following cancer centers and universities have joined the consortium:

  • Indiana University Melvin and Bren Simon Cancer Center
  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University
  • Penn State Hershey Cancer Institute
  • Purdue University Center for Cancer Research
  • The Cancer Institute of New Jersey, scheduled to become part of Rutgers University in July (Rutgers also is set to join the Big Ten Conference in 2014)
  • University of Illinois Cancer Center
  • Holden Comprehensive Cancer Center at the University of Iowa
  • University of Michigan Comprehensive Cancer Center
  • Masonic Cancer Center at the University of Minnesota
  • Fred & Pamela Buffett Cancer Center at the University of Nebraska
  • Carbone Comprehensive Cancer Center at the University of Wisconsin
Related Videos
Thach-Giao Truong, MD
Aparna Parikh, MD
Noman Ashraf, MD
Daniel E. Haggstrom, MD
Daniel E. Haggstrom, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.